WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205745
Description: PWT33597, also known as VDC-597, is an orally bioavailable dual inhibitor of phosphatidylinositide 3-kinase (PI3K) alpha and mammalian target of rapamycin (mTOR) kinase with potential antineoplastic activity. PI3K alpha/mTOR dual inhibitor PWT33597 selectively inhibits both PI3K alpha kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells.
MedKoo Cat#: 205745
Synonym: PWT33597 ; PWT 33597; PWT33597; VDC-597; VDC597; VDC 597.
IUPAC/Chemical Name: NONE
PWT33597 is currently being developed by Pathyway Theraceuptics, which demonstrates excellent in vitro selectivity for its targets, with negligible activity against other lipid kinases, protein kinases and other pharmacologically relevant targets at biologically active concentrations. The compound achieves good distribution into tumors, robust pathway inhibition and excellent oral efficacy in multiple xenograft across varying genetic backgrounds. PWT33597 has an excellent DMPK and safety profile and is an attractive candidate for use as single agent and combination therapy. (source: http://pathwaytx.com/product_pipeline.html).